// App-Quantinova.ai

TPS366 : INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).

Researchers

Presenter

  • Nick Pavlakis

Principal Investigators

  • Kohei Shitara

  • Katrin Marie Sjoquist

  • Andrew James Martin

  • Anthony Jaworski

  • Sonia Yip

  • Do-Youn Oh

  • Markus H. Moehler

  • Tanios S. Bekaii-Saab

  • John Simes

  • David Goldstein

Medical Centers

  • Royal North Shore Hospital, St Leonards, Australia

  • National Cancer Center Hospital, Tokyo, Japan

  • St George Hospital, Sydney, Australia

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • NHMRC CTC, Camperdown, Australia

  • Sydney Catalyst Translational Cancer Research Centre, Sydney, Australia

  • Division of Hematology-Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

  • Johannes-Gutenberg Universitat Mainz, Mainz, Germany

  • Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • Prince of Wales Hospital, University of New South Wales, Cancer Survivors Centre, Sydney, Australia

Locations

  • Australia

  • Japan

  • Republic of South Korea

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Vascular endothelial growth factor A

Drug/Treatment

  • Tipiracil and trifluridine

  • Regorafenib

  • Irinotecan

  • Paclitaxel

  • Docetaxel

  • Nivolumab

  • TAS102

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT04879368

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved